Patients with post polycythemia vera myelofibrosis might experience increased thrombotic risk in comparison to primary and post essential thrombocythemia myelofibrosis (CROSBI ID 313569)
Prilog u časopisu | kratko priopćenje | međunarodna recenzija
Podaci o odgovornosti
Lucijanić, Marko ; Krečak, Ivan ; Sorić, Ena ; Sabljić, Anica ; Galušić, Davor ; Holik, Hrvoje ; Periša, Vlatka ; Morić Perić, Martina ; Zekanović, Ivan ; Kušec, Rajko
engleski
Patients with post polycythemia vera myelofibrosis might experience increased thrombotic risk in comparison to primary and post essential thrombocythemia myelofibrosis
Primary myelofibrosis (PMF), post-polycythemia vera (post-PV) and post-essential thrombocythemia (post-ET) secondary myelofibrosis (SMF) are chronic myeloproliferative neoplasms (MPNs) characterized by bone marrow fibrosis, splenomegaly and debilitating constitutional symptoms. Despite clinical similarities, PMF and SMF harbor different mutational backgrounds [1] and optimal prognostication of risk of death is achieved utilizing specialized prognostic scores (DIPSS [2] and Mysec-PM [3], respectively). PMF and SMF patients also suffer from a substantial risk of thrombotic events that might be comparable to PV and ET patients [4], and is probably modulated by similar factors. Nevertheless, thrombotic risk in myelofibrosis patients is often overlooked and risk-factors for thrombosis are less well characterized. In this report we aimed to assess potential differences in thrombotic risk between PMF, post-PV and post-ET SMF in our multicentric cohort of patients with myelofibrosis.
post polycythemia vera ; myelofibrosis ; post-essential thrombocythemia ; secondary myelofibrosis
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
Podaci o izdanju
Povezanost rada
Kliničke medicinske znanosti